2Mckeever PE,Ross DA,Strawderman MS,et al.Comparison of the predictive power for survival in gliomas provided by MIB-1,bromodeoxyuridine and proliferating cell nuclear antigen with histopathoogic and clinical parametes[J].J Neuropathol Exp Neurol,1997,56:798-805.
3Hsu DW,Louis DN,Efird JT,et al.Use of MIB-1(Ki-67)immunoreactivity in differentiating grade Ⅱ and grade Ⅲ gloimas.J Neuropathol Exp Neurol[J].1997,56:857-865.
4Mckeever PE,Strawderman MS,Yamini B,et al.MIB-1 proliferation index predicts survival among patients with grade Ⅱ astrocytoma[J].J Neuropathol Exp Neurol,1998,57:931-936.
5Enestrom S,Vavruch I,Franlund B,et al.Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas[J].Neurochirurgie,1998,44:25-30.
6Pierce E,Doshi R,Deane R.PCNA and Ki-67 labelling indices in pre-irradiated and post-irridiated astrocytomas:a comparative immunohistochemical analysis for evaluation of proliferative activity[J].Mol Pathol,1998,51:90-95.
7Litofasky NS,Mix TC,Baker SP,et al.Ki-67(clone MIB-1)proliferation index in recurrent glial neoplasms:no prognostic significance[J].Surg Neurol,1998,50:579-585.
8Pollack IF,Campbell JW,Hamiliton RL,et al.Proliferation index as a predictor of prognosis in malignant gliomas of childhood[J].Cancer,1997,79:849-856.
9Wakimoto H,Aoyagi M,Nakayama T,et al.Prognostic significance of Ki-67 labeling indices obained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas[J].Cancer,1996,77:373-380.
10Nazzaro JM,Neuwelt EA.The role of surgery in the management of supratentorial intermediade and high-grade astrocytomas in adults[J].J Neurosurg,1990,73:331-344.
